Grant: CIHR Fellowship
University of Alberta
$90,000.00
Identification of Novel Granzyme B Substrates and Characterization of Critical Residues of a Granzyme B Inhibitor, Serpina3n.
EF 2008-09
Résumé
Granzyme B (GrB) is a protein released by a specific type of white blood cell called a cytotoxic T lymphocyte (CTL). CTL cells recognize tumor and virus infected cells and destroy these cells by releasing GrB. This is one of the strategies used by the immune system to limit the spread of infection. After GrB enters the infected cells, it works by activating a sequence of reactions inside the cell that ultimately results in DNA destruction and cell death. Proteins that inhibit GrB are excellent candidates as drugs that suppress the immune system. The first goal of my project is to engineer an enhanced GrB inhibitor by combining the structural components of these inhibitors that confer the greatest suppressive effects. Another goal of my research is to identify new targets of GrB to further define the exact sequence of reactions downstream of GrB. This new understanding will generate potential drug targets in the treatment of autoimmune diseases such as multiple sclerosis and transplant rejection.
Our laboratory first discovered GrB in 1985, and delineated this pathway in the involvement of CTL killing of infected cells. More recently, we described a new GrB inhibitor called serpina3n. I plan to expand on the knowledge and expertise we have generated in this field by pursuing the GrB research as it relates to health and disease.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
173593
Name
Marcet Palacios Marcelo
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Identification of Novel Granzyme B Substrates and Characterization of Critical Residues of a Granzyme B Inhibitor, Serpina3n.
Programtype2
Fellowship Programs
Orgnameinp2
University of Alberta
Cihramount2
$90,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Apoptosis; Autoimmune Diseases; Molecular Biology Techniques; Protein Synthesis And Purification
Abstract
Granzyme B (GrB) is a protein released by a specific type of white blood cell called a cytotoxic T lymphocyte (CTL). CTL cells recognize tumor and virus infected cells and destroy these cells by releasing GrB. This is one of the strategies used by the immune system to limit the spread of infection. After GrB enters the infected cells, it works by activating a sequence of reactions inside the cell that ultimately results in DNA destruction and cell death. Proteins that inhibit GrB are excellent candidates as drugs that suppress the immune system. The first goal of my project is to engineer an enhanced GrB inhibitor by combining the structural components of these inhibitors that confer the greatest suppressive effects. Another goal of my research is to identify new targets of GrB to further define the exact sequence of reactions downstream of GrB. This new understanding will generate potential drug targets in the treatment of autoimmune diseases such as multiple sclerosis and transplant rejection.
Our laboratory first discovered GrB in 1985, and delineated this pathway in the involvement of CTL killing of infected cells. More recently, we described a new GrB inhibitor called serpina3n. I plan to expand on the knowledge and expertise we have generated in this field by pursuing the GrB research as it relates to health and disease.
Competitiondate
200810
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Marcet Palacios, Marcelo
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $90,000~ $0~